![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, February 04, 2011 10:53:50 AM
Research and Markets: Competitor Analysis: G-CSF and GM-CSF 2011
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/44f15d/competitor_analysi) has announced the addition of the "Competitor Analysis: G-CSF and GM-CSF" report to their offering.
The present Competitive Intelligence Report about G-CSF & GM-CSF products in the pipeline and off-patent products provides a competitor evaluation in the field of G-CSF & GM-CSF branded products in regulated markets and products in non-regulated markets, biosimilars (biogenerics, follow-on biologics) and next generation, longer acting products or new uses of G-CSF as of January 2011. Purchase of the downloadable PDF report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently marketed branded and non-branded G-CSF and GM-CSF products in regulated and non-regulated markets for treatment of chemotherapy-induced neutropenia. The report includes the market size of branded G-CSF products in 2009. It lists the most advanced biosimilars of G-CSF and pegylated G-CSF and of GM-CSF. It describes the companies with G-CSF and GM-CSF products and of pegylated versions in non-regulated markets. In addition, the report lists company-specific R&D pipelines of G-CSF/GM-CSF products and projects. Competitor projects are listed in a tabular format providing Information on:
* Drug Codes,
* Target / Mechanism of Action,
* Class of Compound,
* Company,
* Territory,
* Indication,
* R&D Stage and
* additional comments with a hyperlink leading to the source of information.
Key Topics Covered:
* 1st Generation branded G-CSF products in regulated markets
* Biosimilar 1st generation G-CSF products in regulated markets
* Next generation G-CSF products and uses in regulated markets
* Biosimilar next generation G-CSF products and uses in regulated markets
* 1st generation G-CSF products in non-regulated markets
* Next generation G-CSF products in non-regulated markets
* 1st and next generation GM-CSF products in regulated markets
* 1st and next generation GM-CSF products in non-regulated markets
* About La Merie
48 Companies Mentioned, Some Include:
Corporate G-CSF & GM-CSF R&D Pipelines
* Acorn Biomedical
* Amgen
* Apricus Biosciences
* Beijing SL
* Pharmaceutical Co
* Bolder BioTechnology
* Cangene
* Dong-A Pharmaceutical
* Fuji Pharma
* Genzyme
* Green Cross
* Hospira
* Intas Biopharmaceuticals
* Kyowa Hakko Kirin Pharma
* NCPC GeneTech Biotechnology Development
* Octapharma
* Phage Pharmaceuticals
* PharmaEssentia
* Recoly
* Reliance GeneMedix
* Reliance Life Sciences
* Serum Institute of India
* Shandong GeneLeuk Biopharma
* USV Ltd.
* Xiamen Amoytop Biotech
* Zenotech Laboratories
* Zydus Cadila
Alliance Creative Group (ACGX) Releases Q2 2024 Financial and Disclosure Report with an increase of over $130,000 in Net Income from Q2 2023 to Q2 2024 • ACGX • Aug 14, 2024 8:30 AM
Avant Technologies Unveils AI-Powered Healthcare Infrastructure to Deliver Intelligent Healthcare Solutions • AVAI • Aug 14, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q2 FY2024 Financial Results • SNWV • Aug 13, 2024 7:11 AM
Kona Gold Beverages, Inc. Nears Completion of Reverse Merger with New Candidate • KGKG • Aug 12, 2024 10:00 AM
Maybacks Global Entertainment and DigiTrax Entertainment Sign Agreement to Broadcast "Karaoke Cloud" on iDreamCTV • AHRO • Aug 12, 2024 8:45 AM
HealthLynked Partners with RxSpark to Enhance Medication Access and Management for Patients • HLYK • Aug 12, 2024 8:00 AM